S109: ACTIVATION OF PYRUVATE KINASE-R WITH ETAVOPIVAT (FT-4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS

oleh: M Telen, S Saraf, K Cruz, M Idowu, T Kalfa, I Osunkwo, R Hagar, J Geib, S Forsyth, P Schroeder, E Wu, P Kelly, R Brown

Format: Article
Diterbitkan: Wiley 2022-01-01

Deskripsi

No description available for this item.